Additional analyses of the 2-year trial data showed that the improvement in inflammatory burden was present in ACPA-positive and ACPA-negative patients at increased risk for RA, but not in ACPA-negative patients who retrospectively had a low risk for RA.12 This evidence concerns the gene PRTN3 and rheumatoid arthritis.